Pyrimidine compound, EGFR inhibitor and application of EGFR inhibitor

A compound and pyrimidine technology, applied in the field of medicine, can solve the problems of severe rash and side effects in patients, poor efficacy in drug-resistant patients, etc., and achieve the effects of low toxicity, reduced inhibitory activity, and reduced mutation selectivity

Inactive Publication Date: 2016-11-09
TETRANOV PHARMA CO LTD
View PDF0 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the second-generation inhibitors also have strong wild-type EGFR inhibitory activity, and the inhibitory activity to wild-type EGFR is si

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrimidine compound, EGFR inhibitor and application of EGFR inhibitor
  • Pyrimidine compound, EGFR inhibitor and application of EGFR inhibitor
  • Pyrimidine compound, EGFR inhibitor and application of EGFR inhibitor

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0072] The preparation method of intermediate A is method A1, method A2 or method A3, specifically as follows.

[0073] Method A1: Add 7.8mmol of compound a1-1 to a 100ml single-necked bottle, add 3ml of diisopropylethylamine and 30ml of n-butanol to obtain a mixture; use a cold bath to cool the mixture to -20°C, and slowly Add compound a2 (13.8mmol) dropwise, react at low temperature for 1h after the addition, remove the cooling bath and warm up to room temperature, stir overnight, evaporate the solvent to dryness under reduced pressure, add 100ml of ethyl acetate (EA) to the residue, and then add 50ml washed with water twice, the organic phase was evaporated to dryness, and the residue was separated by column chromatography (eluent: ethyl acetate:petroleum ether=1:30 (volume ratio)) to obtain intermediate A1.

[0074] The reaction formula that above-mentioned method A1 involves is as follows:

[0075]

[0076] Wherein, Ar is selected from phenyl or substituted phenyl, an...

Embodiment 1

[0117] The pyrimidine compound of the present embodiment has a structural formula as shown in formula I-1:

[0118]

[0119] The preparation method of the pyrimidine compound of the present embodiment is as follows: 50mg (0.15mmol) of intermediate B, 150mg (0.5mmol) of intermediate A and 35mg (0.18mmol) of p-toluenesulfonic acid monohydrate are dissolved in 5ml of 2 -amyl alcohol, then warming up to 50°C, stirring overnight under nitrogen protection, TLC showed that the raw material basically disappeared, spin to dry volume, then add 20ml dichloromethane and 20ml saturated aqueous sodium carbonate solution, separate layers, then wash with 20ml dichloromethane The aqueous phase was collected twice, and the organic phase was combined, dried and spin-dried, and separated by TLC to obtain 20 mg of the product, which was compound I-1. The analytical data of this compound are as follows: 1H-NMR (400MHz, CDCl 3 ): δ: 10.18 (br, 1H); 9.19 (br, 1H); 8.38 (s, 1H); 7.52 (dt, J = 2.39...

Embodiment 30

[0135] The pyrimidine compound of the present embodiment is the mesylate of the pyrimidine compound (I-6) shown in Example 6, and its structural formula is as shown in formula I-30:

[0136]

[0137] The preparation method of the pyrimidine compound (methanesulfonate) of this example is: add 0.37g of compound I-6 into a 50ml one-mouth bottle, add 10ml of acetone and 1ml of water, and slowly add it under stirring after the addition After adding 64mg of methanesulfonic acid, react at 50°C for 3h, evaporate the reaction solution to dryness, add 6ml of acetonitrile and heat up to 70°C, stir for 30min, cool slowly to precipitate the solid, filter the solid, wash with acetonitrile, After drying, 140 mg of a white solid was obtained, namely compound I-30. Its purity was 98.5% as detected by HPLC. The analytical data of gained compound 1-30 is: HNMR (400M, d 6 -DMSO): 9.35(s1H), 9.14(s,1H), 8.76(s,1H), 8.70(s,1H), 8.36(s,1H), 7.95(s,2H), 7.85(d,J= 8.10Hz, 1H), 7.41(m, 2H), 6.97(...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pyrimidine compound, an EGFR inhibitor and application of the EGFR inhibitor. The pyrimidine compound is prepared from a compound shown in the formula I or pharmaceutically acceptable salt thereof, a stereoisomer, and a solvate or prodrug. The EGFR inhibitor contains the pyrimidine compound. The pyrimidine compound can inhibit activated or resistant mutation of one or more kinds of EGFRs, can inhibit proliferation of the EGFR T790M/L858R double-mutant enzyme in the nanomolar concentration, but has a weak inhibiting effect on the wild EGFR enzyme; the pyrimidine compound is applicable to treatment of the EGFR-sensitive mutations cancer and also suitable for cases with secondary dug resistance in present EGFR-TKI treatment; meanwhile, toxic and side effects caused by inhibition on the wild EGFR are greatly reduced due to the mutation selectivity of the pyrimidine compound, and the pyrimidine compound is an ideal treatment drug for diseases caused by EGFR mutation.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to a pyrimidine compound, and also relates to an EGFR inhibitor and its preparation for regulating EGFR tyrosine kinase activity or treating EGFR-related diseases, especially non-small cell lung cancer. Applications. Background technique [0002] Epidermal Growth Factor Receptor EGFR (Epidermal Growth Factor Receptor) is a transmembrane protein tyrosine kinase of the erbB receptor family. When it binds to a growth factor ligand such as epidermal growth factor (EGF), the receptor can homodimerize with an additional EGFR molecule, or with another family member such as erbB2 (HER2), erbB3 (HER3) , or erbB4 (HER4)) undergoes heterodimerization. Homodimerization and / or heterodimerization of the erbB receptor leads to phosphorylation of key tyrosine residues in the intracellular domain and to stimulation of many intracellular signaling pathways involved in cell proliferation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D239/48A61K31/505A61K31/506A61K31/5377A61P35/00A61P3/10A61P37/00A61P25/00A61P9/00
CPCC07D239/48C07D401/12C07D403/12A61K31/505A61K31/506A61K31/5377A61P3/10A61P9/00A61P25/00A61P35/00A61P37/00
Inventor 吴豫生牛成山耿阳梁阿鹏郭中伟刘建涛杨俊亮霍云峰韩兴旺孟庆国李敬亚郭瑞云邹大鹏
Owner TETRANOV PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap